Pangea Biomed

Company Overview

Snapshot

Founded in March 2018 by Ze’ev Ronai, Eyal Gottlieb, and Eytan Ruppin, Pangea Biomed operates with 11–50 employees. The company has raised $12 million across two funding rounds from two investors. In December 2022, Pangea Biomed secured additional seed funding, reinforcing its development of advanced multi-cancer response prediction technology.

Business overview

Pangea Biomed develops ENLIGHT, a pan-cancer, pan-therapy response predictor that leverages machine learning, artificial intelligence, and deep RNA analysis to personalize cancer care. The company's unsupervised machine-learning approach ensures ENLIGHT's scalability and effectiveness during drug development, even without prior clinical data. Pangea also develops EnlightDP, a response prediction technology based on analyzing digital H&E slide images using its proprietary RNA expression imputation platform. The company aims to enhance precision oncology for patients, improve drug development, and empower oncologists, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Pharma & Medical Biotechnology.

Strategic signal

In December 2022, Pangea Biomed announced additional seed funding, bringing its total raised to $12 million. This capital infusion signals continued investor confidence in the company's multi-cancer response predictor technology and its potential to advance precision oncology. The funding supports further development and validation of ENLIGHT, indicating a strong trajectory for Pangea Biomed in a competitive and rapidly evolving market.

Company Intelligence Q&A

What is Pangea Biomed's core technology?

Pangea Biomed's core technology is ENLIGHT, an advanced pan-cancer, pan-therapy response predictor that uses machine learning, artificial intelligence, and deep RNA analysis to personalize cancer care. This technology is designed to be scalable and effective during drug development, even when clinical data is not yet available.

When was Pangea Biomed founded and by whom?

Pangea Biomed was founded in March 2018 by co-founders Ze’ev Ronai, Eyal Gottlieb, and Eytan Ruppin.

What was a significant funding event for Pangea Biomed?

In December 2022, Pangea Biomed added $5 million in additional seed funding, contributing to a total of $12 million raised. This round saw participation from NFX Capital and Danny Tocatly.

What is EnlightDP?

EnlightDP is a response prediction technology developed by Pangea Biomed. It is based on the analysis of digital H&E slide images, utilizing the company's proprietary RNA expression imputation platform.

What is Pangea Biomed's primary goal?

Pangea Biomed aims to bring effective precision oncology to cancer patients, improve oncology drug development processes, and empower oncologists to treat patients with greater success.